Aidan studies Mathematics and German, serving as Vice President and Partnerships Lead at Big Green Capital. His research interests span equity analysis across biotech, technology, and industrials, with a focus on fundamental valuation and short-side idea generation. He also serves as a Project Manager at Evergreen AI and independently sourced and closed BGC’s first institutional partnership with Wall Street Oasis. Aidan interns in private equity at Evolis Capital in Montreal, where he supports deal sourcing, due diligence, and financial modeling for lower middle-market acquisitions. Outside of the markets, he enjoys traveling throughout Europe and playing golf.

Soleno Therapeutics is a rare-disease biotech company with a monopoly-esque advantage in treating Prader-Willi syndrome hyperphagia centered around VYKAT XR, which is currently the only FDA approved product to treat a condition that has seen each and every competitor fail thus far. The company has already seen impressive traction since launch, with Q3 revenue reaching $66M and fast patient onboarding demonstrating strong market demand. Despite this, the company continues to trade at distressed levels following the controversial actions of Scorpion Capital and the baseless allegation of a patient death that had nothing to do with the company. As there is no viable competitor until at least 2028, and discontinuation rates are consistent with industry norms, we believe Soleno represents a prototypical biotech rerating scenario where the company will see a misunderstanding regarding its safety profile unwind, impressive visibility driven revenue growth, and a one-off product story develop into a solid earnings story.